3 recruiting, 2 active not recruiting, 2 completed. 6 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 3, Active not recruiting 2, Completed 1 |
| Phase 2 | 4 | Recruiting 2, Active not recruiting 1, Completed 1 |
Follow LB100: new trials by email Literature Review of LB100 trials Research Report on LB100
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients LB-100, Atezolizumab - Metastatic Microsatellite-stable Colorectal Cancer | Phase 1 | Recruiting | The Netherlands Cancer Institute | 37 | 2024-06-18 | 2026-06-29 |
| Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 Dostarlimab, LB-100 - Ovarian Clear Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 21 | 2023-11-10 | 2026-06-23 |
| Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas LB-100 plus Doxorrubicin, Doxorubicin - Advanced Soft-tissue Sarcoma | Phase 1 / Phase 2 | Active not recruiting | Grupo Espanol de Investigacion en Sarcomas | 152 | 2023-05-29 | 2025-03-21 |
| LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer Atezolizumab, Carboplatin, Etoposide - Extensive Stage Lung Small Cell Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 3 | 2021-05-28 | 2026-04-07 |
| A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) LB-100 - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | Lixte Biotechnology Holdings, Inc. | 47 | 2019-04-01 | 2019-04-08 |
| Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma LB-100 - Astrocytoma, Grades II, III and IV, Glioblastoma Multiforme | Phase 2 | Completed | National Cancer Institute (NCI) | 7 | 2019-01-09 | 2023-11-22 |
| Phase I Study of LB-100 With Docetaxel in Solid Tumors LB-100 for Injection, Docetaxel - Tumors, Neoplasms | Phase 1 | Completed | Lixte Biotechnology Holdings, Inc. | 29 | 2013-02-01 | 2017-01-24 |
Astrocytoma (1) · Brain Neoplasms (1) · Colorectal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Glioblastoma (1) · Glioma (1) · Myelodysplastic Syndromes (1) · Neoplasms (1) · Oligodendroglioma (1)
Lixte Biotechnology Holdings, Inc. (2) · City of Hope Medical Center (1) · Grupo Espanol de Investigacion en Sarcomas (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · The Netherlands Cancer Institute (1)
United States (5) · Netherlands (1) · Spain (1)
Aaron Mansfield, MD (1) · Amir Jazaeri, M D (1) · Carlos Becerra, MD (1) · Donald Richards, MD (1) · Eric C Burton, M.D. (1) · Fadi Braiteh, MD (1) · Neeltje Steeghs, MD, PhD (1) · Rami Komrokji, MD (1) · Ravi Salgia (1) · Vincent Chung, MD, FACP (1)
PMID 38932511, PMID 28039265, PMID 37584370
P30CA033572 (1)